ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at American Association for Cancer Research-National Cancer Institute-EORTC Conference

Published: Oct 21, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ImmunoGen, Inc. (Nasdaq: IMGN) today announced the presentation of interim data from the ongoing Phase I trial of Sanofi’s SAR566658 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting (abstract #A73) being held in Boston. SAR566658 is an ADC targeted to CA6, which is found on many cases of ovarian, breast, and other epithelial cancers. The data reported support that SAR566658 is generally well tolerated and can induce objective responses and sustained stable disease in heavily pretreated patients with CA6-positive cancers.

Help employers find you! Check out all the jobs and post your resume.

Back to news